SUTENT

LOE Approaching

sunitinib malate

NDAORALCAPSULEPriority Review
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT05800106Phase 1Completed

A Bioequivalence Study of Sunitinib Malate Capsules.

Started Dec 2018
NCT03541902Phase 2Active Not Recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Started May 2018
32 enrolled
Malignant Neoplasms of Urinary TractRenal Cell CarcinomaChromophobe Renal Cell Carcinoma+6 more
NCT02187042N/ACompleted

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

Started Oct 2015
70 enrolled
Metastatic/Advanced Renal Cell Carcinoma
NCT02068586Phase 2Active Not Recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Started Nov 2014
210 enrolled
Ciliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeIris Melanoma+9 more
NCT02184416N/ACompleted

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

Started Oct 2014
554 enrolled
Metastatic Renal Cell Carcinoma (mRCC)
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.